口服固体製剂市场规模、份额、成长分析、按产品类型、按机制、按最终用户、按地区 - 行业预测，2024-2031

2022年口服固体製剂市场规模将为6066亿美元，预测期内（2024-2031年）复合年增长率为6.4%，从2023年的6454.2亿美元增至2031年的1.6兆美元。至7000万美元。

在几个关键因素的推动下，口服固体製剂市场近年来出现了显着成长。其中包括口服药物需求的增加、製剂技术的进步以及需要长期药物治疗的人口老化。此外，药物输送方法的创新意义重大，可以提高患者的依从性和疗效。监管机构为确保品质和安全而实施的严格监管正在刺激製药公司增加研发投资。製药公司和受託製造厂商之间的合作也有助于扩大产品范围。简而言之，随着医疗保健产业的不断变化，口服固体製剂市场预计将进一步扩大和发展。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 市场生态系统
• Start-Ups分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

全球口服固体製剂市场：依产品类型

• 市场概况
• 药片
  • 常规/立即发布
  • 缓释製剂
  • 咀嚼锭
  • 发泡
• 胶囊
  • 硬明胶胶囊
  • 软明胶胶囊
• 粉末/颗粒
• 锭剂
• 软糖

全球口服固体製剂市场：按机制

• 市场概况
• 控制释放型
• 立即释放
• 延迟释放

全球口服固体製剂市场：依最终用户分类

• 市场概况
• 大公司
• 中型企业/中小企业
• 其他（Start-Ups公司/学名药公司）

全球口服固体製剂市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（United Kingdom）
• Sanofi SA（France）
• Merck & Co., Inc.（United States）
• Johnson & Johnson（United States）
• AstraZeneca PLC（United Kingdom）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• Roche Holding AG（Switzerland）
• Bristol Myers Squibb（United States）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Boehringer Ingelheim GmbH（Germany）
• Mylan NV（Netherlands）
• Takeda Pharmaceutical Company Limited（Japan）
• Daiichi Sankyo Company, Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Sandoz International GmbH（Germany）

Oral Solid Dosage Pharmaceutical Formulation Market size was valued at USD 606.6 Billion in 2022 and is poised to grow from USD 645.42 Billion in 2023 to USD 1060.17 Billion by 2031, at a CAGR of 6.4% during the forecast period (2024-2031).

The Oral Solid Dosage Pharmaceutical Formulation Market has seen significant growth recently, propelled by several key factors. These include rising demand for oral medications, advancements in drug formulation technologies, and an aging population requiring prolonged pharmaceutical treatment. Moreover, there have been notable innovations in drug delivery methods, leading to enhanced patient compliance and efficacy. Stringent regulations by regulatory bodies ensuring quality and safety have spurred pharmaceutical companies to increase investments in research and development. Collaborations between pharmaceutical firms and contract manufacturing organizations have also been instrumental in broadening product offerings. In summary, the market for oral solid dosage pharmaceutical formulations is set to expand further and evolve amidst ongoing changes in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Oral Solid Dosage Pharmaceutical Formulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Oral Solid Dosage Pharmaceutical Formulation Market Segmental Analysis

The global Oral solid dosage pharmaceutical formulation market is segmented on the basis of product type, mechanism, end-user and region. Based on product type, Tablets (Conventional/Immediate Release, Modified Release, Chewable Tablets, Effervescent Tablets), Capsules (Hard Gelatin Capsules, Soft Gelatin Capsules), Powders & Granules, Lozenges & Pastilles, and Gummies. Based on mechanism, the market is segmented as Controlled-release, Immediate-release, and Delayed-release. Based on end-user, it is segregated into Large-size Companies, Medium- & Small-size Companies, and Others (Startups & Generic Pharmaceutical Companies). Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Oral Solid Dosage Pharmaceutical Formulation Market

Innovations such as 3-D printing, nanotechnology, and advanced drug delivery systems are improving the performance and effectiveness of oral solid dosage medications. These advancements not only enhance patient compliance but also empower pharmaceutical companies to develop new formulations, driving market growth.

Restraints in the Oral Solid Dosage Pharmaceutical Formulation Market

The pharmaceutical industry faces rigorous scrutiny from regulatory agencies worldwide to ensure drug safety and efficacy. These lengthy and complex approval processes can lead to delays in product launches, increased development costs, and hinder market access for new entrants. Meeting these stringent regulatory requirements continues to be a major challenge in the industry.

Market Trends of the Oral Solid Dosage Pharmaceutical Formulation Market

Progress in genetic profiling and biomarker identification has enabled pharmaceutical companies to create medications tailored to the specific needs of individual patients. This development not only improves treatment outcomes but also encourages patient adherence, fostering niche markets for precision oral solid dosage formulations. With the healthcare sector increasingly emphasizing patient-centered approaches, there is anticipated significant growth in demand for personalized oral solid dosage medications.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Oral Solid Dosage Pharmaceutical Market by Product Type

• Market Overview
• Tablets
  • Conventional/Immediate Release
  • Modified Release
  • Chewable Tablets
  • Effervescent Tablets
• Capsules
  • Hard Gelatin Capsules
  • Soft Gelatin Capsules
• Powders & Granules
• Lozenges & Pastilles
• Gummies

Global Oral Solid Dosage Pharmaceutical Market by Mechanism

• Market Overview
• Controlled-release
• Immediate-release
• Delayed-release

Global Oral Solid Dosage Pharmaceutical Market by End User

• Market Overview
• Large-size Companies
• Medium- & Small-size Companies
• Others (Startups & Generic Pharmaceutical Companies)

Global Oral Solid Dosage Pharmaceutical Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments